Recommendations in Covid

During the COVID-19 pandemic, as an emergency, fast-track guideline development, based on the order commission of the Minister of Health dated 27 March 2020, the Agency published the first version of the Recommendations in COVID-19 prepared in collaboration with an interdisciplinary Team of Clinical Experts (in areas from anesthesiology and intensive care, infectious diseases, laboratory diagnostics, epidemiology, microbiology, virology, pulmonology, radiology, to psychiatry and emergency medicine), coordinated by the Steering Committee, composed of the Presidium of the Transparency Council of the Agency for Health Technology Assessment and Tariff Systems.

Polish diagnostic, therapeutic and organizational recommendations for the care of persons infected or exposed to SARS-CoV-2 – version 1.0, April 25, 2020. (EN)

In view of the rapidly changing pandemic situation and the continuous influx of new scientific evidence for the clinical efficacy and safety of medical technologies used in COVID-19, the Agency is engaged in a process of continuously updating the Recommendations. The current sets of recommendations for diagnosis, pharmacotherapy, and long COVID/post-COVID

• DIAGNOSTICS
• PHARMACOTHERAPY
• LONG COVID/POST-COVID

Due to the declining epidemic threat of COVID-19, recommendations for diagnostic management have been developed.

Zalecenia postępowania diagnostycznego w sytuacji zmniejszenia zagrożenia epidemicznego związanego z COVID-19 (wersja 1.1, 7 kwietnia 2022 r.) (Recommendations for diagnostic management in case  of COVID-19 epidemic risk reduction – version 1.1, April 7, 2022) pl

Analytical materials:

Tocilizumab w COVID-19 – Aktualizacja (wersja 1.3, 3 lutego 2022 r.) (Tocilizumab in COVID-19 – Rapid Review update (version 1.3, 3 February 2022) pl

Remdesivir w COVID-19 – Aktualizacja (wersja 1.3, 3 lutego 2022 r.) (Remdesivir in COVID-19 – Rapid Review update (version 1.3, 3 February 2022) pl

Anakinra w COVID-19 – Aktualizacja (wersja 1.3, 10 lutego 2022 r.) (Anakinra in COVID-19 – Rapid Review update (version 1.3, 10 February 2022) pl

Nirmatrelvir + Ritonavir w COVID-19 – Rapid Review (wersja 1.0, 17 lutego 2022 r.) (Nirmatrelvir + Ritonavir in COVID-19 – Rapid Review (version 1.0, 17 February 2022) pl

Molnupiravir w COVID-19 – Rapid Review (wersja 1.0, 11 stycznia 2022 r.) (Molnupiravir in COVID-19 – Rapid Review (version 1.0, 11 February 2022) pl

Sotrovimab w COVID 19 – Rapid Review (wersja 1.1, 30 listopada 2021 r.) (Sotrovimab in COVID-19 – Rapid Review (version 1.1, 30 November 2021) pl

Fluwoksamina w COVID 19 – Rapid Review (wersja 1.0, 26 listopada 2021 r.) (Fluvoxamine in COVID-19 – Rapid Review (version 1.0, 26 November 2021) pl

Osocze ozdrowieńców w COVID-19 – Rapid Review (wersja 1.3, 29 października 2021 r.) (Convalescent plasma in COVID-19 – Rapid Review update (version 1.3, 29 October 2021) pl

Bamlanivimab ± etesevimab ( w COVID-19 – Rapid review (wersja 1.2, 1 października 2021 r.) (Bamlanivimab ± etesevimab in COVID-19 – Rapid Review update (version 1.2, 1 October 2021) pl

REGN-COV2 w COVID-19 – Rapid review (wersja 1.3, 27 września 2021 r.) (REGN-COV2 in COVID-19 – Rapid Review update (version 1.3, 27 September 2021) pl

Baricitinib w COVID-19 – Rapid Review (wersja 1.1, 15 września 2021 r.) (Baricitinib in COVID-19 – Rapid Review update (version 1.1, 15 September 2021) pl

Ivermectin w COVID-19 – Rapid Review (wersja 1.2, 6 sierpnia 2021 r.) (Ivermectin in COVID-19 – Rapid Review update (version 1.2, 6 August 2021) pl

Sulodexide in COVID-19 – Rapid Review (wersja 1.0, 12 lipca 2021 r.) (Sulodexide in COVID-19 – Rapid Review (version 1.0, 12 July 2021) pl

Sarilumab in COVID-19 – Rapid Review (wersja 1.0, 12 lipca 2021 r.) (Sarilumab in COVID-19 – Rapid Review (version 1.0, 12 July 2021) pl

Tofacitinib in COVID-19 – Rapid Review (wersja 1.0, 12 lipca 2021 r.) (Tofacitinib in COVID-19 – Rapid Review (version 1.0, 12 July 2021) pl

REGN-COV2 in COVID-19 – Rapid review (wersja 1.2, 22 czerwca 2021 r.) (REGN-COV2 in COVID-19 – Rapid Review update (version 1.2, 22 June 2021) pl

Leki przeciwzakrzepowe w COVID-19 – Rapid Review (wersja 1.2, 18 czerwca 2021 r.) (Antithrombotic therapy in COVID-19 – Rapid Review update (version 1.2, 18 June 2021) pl

Antybiotyki w COVID-19 – Rapid Review (wersja 1.0, 15 czerwca 2021 r.) (Antibiotics in COVID-19 – Rapid Review (version 1.0, 15 June 2021) pl

Kortykosteroidy w COVID-19 – Rapid Review (wersja 1.2, 10 czerwca 2021 r.) (Corticosteroids in COVID-19 – Rapid Review update (version 1.2, 10 June 2021) pl

Anakinra w COVID-19 – Rapid review (wersja 1.1, 8 czerwca 2021 r.) (Anakinra in COVID-19 – Rapid Review update (version 1.1, 8 June 2021) pl

Lenzilumab w COVID-19 – Rapid Review (wersja 1.0, 11 czerwca 2021 r.) (Lenzilumab in COVID-19 – Rapid Review (version 1.0, 11 June 2021) pl

Sotrowimab w COVID 19 – Rapid Review (wersja 1.0, 11 czerwca 2021 r.) (Sotrowimab in COVID-19 – Rapid Review (version 1.0, 11 June 2021) pl

Osocze ozdrowieńców w COVID-19 – Rapid Review (wersja 1.2, 27 maja 2021 r.) (Convalescent plasma in COVID-19 – Rapid Review update (version 1.2, 27 May 2021) pl

Iwermektyna w COVID-19 – Rapid Review (wersja 1.1, 21 maja 2021 r.) (Ivermectin in COVID-19 – Rapid Review update (version 1.1, 21 May 2021) pl

Baricitinib w COVID-19 – Rapid Review (wersja 1.0, 18 maja 2021 r.) (Baricitinib in COVID-19 – Rapid Review (version 1.0, 18 May 2021) pl

Macierzyste komórki mezenchymalne w COVID-19 – Rapid Review (wersja 1.0, 27 kwietnia 2021 r.) (Mesenchymal stem cells in COVID-19 – Rapid Review (version 1.0, 27 April 2021) pl

Wziewne kortykosteroidy w COVID-19 – Rapid Review (wersja 1.0, 27 kwietnia 2021 r.) (Inhaled corticosteroids in COVID-19 – Rapid Review (version 1.0, 27 April 2021) pl

Produkty z osocza ludzkiego (immunoglobuliny) w COVID-19 – Rapid Review (wersja 1.0, 22 April 2021 r.) (Human plasma–derived therapies (immunoglobulines) in COVID-19 –Rapid Review (version 1.0, 22 April 2021) pl

Baricitinib + remdesivir w COVID-19 – Rapid Review (wersja 1.0, 23 kwietnia 2021 r.) (Baricitinib + remdesivir in COVID-19 – Rapid Review (version 1.0, 23 April 2021) pl

Regdanwimab w COVID-19 – Rapid Review (wersja 1.0, 6 kwietnia 2021 r.) (Regdanwimab in COVID-19 – Rapid Review (version 1.0, 6 April 2021) pl 

Favipiravir w COVID-19 – Rapid Review – Aktualizacja (wersja 1.1, 24 marca 2021 r.) (Favipiravir in COVID-19 – Rapid Review – update (version 1.1, 24 March 2021) pl

Bamlanivimab (LY-CoV555) w COVID-19 – Rapid Review – Aktualizacja (wersja 1.1, 23 marca 2021 r.) (Bamlanivimab (LY-CoV555) in COVID-19 – Rapid Review update (version 1.1, 23 March 2021) pl

Tocilizumab w COVID-19 – Rapid Review – Aktualizacja (wersja 1.1, 12 marca 2021 r.) (Tocilizumab in COVID-19 – Rapid Review update (version 1.1, 12 March 2021) pl

Ivermectin w COVID-19 – Rapid Review (wersja 1.0, 4 lutego 2021 r.) (Ivermectin in COVID-19 – Rapid Review (version 1.0, 4 February 2021) pl

Remdesivir w COVID-19 – Rapid Review – Aktualizacja (wersja 1.1, 20 Listopada 2020 r.) (Remdesivir in COVID-19 – Rapid Review update (version 1.1, 20 November 2020) pl

Kwas acetylosalicylowy i klopidogrel w COVID-19 – Rapid Review (wersja 1.0, 20 listopada 2020 r.) (Acetylsalicylic acid and clopidogrel in COVID-19 – Rapid Review (version 1.0, 20 November 2020) pl

Amantadyna w COVID-19 – Rapid Review (wersja 1.1, 19 listopada 2020 r.) (Amantadine in COVID-19 – Rapid Review update (version 1.1, 19 November 2020) pl

Interferon beta w COVID-19 – Rapid Review (wersja 1.0, 16 listopada 2020 r.) (Interferon beta in COVID-19 – Rapid Review (version 1.0, 16 November 2020) pl

Hydroksychlorochina i chlorochina w COVID-19 – Rapid Review (wersja 1.0, 14 paździenika 2020 r.) (Hydroxychloroquine and chloroquine in COVID-19 – Rapid Review (Version 1.0, 14 October 2020) pl

Lopinavir/ritonavir w COVID-19 – Rapid Review (wersja 1.0, 5 sierpnia 2020 r.) (Lopinavir/ritonavir in COVID-19 – Rapid Review (version 1.0, 5 August 2020) pl

Lopinavir/ritonavir in COVID-19 – Rapid Review (version 1.0, 5 August 2020) en

Archive: